CL2017000885A1 - Anticuerpos anti-ox40 humanizados y usos de los mismos - Google Patents
Anticuerpos anti-ox40 humanizados y usos de los mismosInfo
- Publication number
- CL2017000885A1 CL2017000885A1 CL2017000885A CL2017000885A CL2017000885A1 CL 2017000885 A1 CL2017000885 A1 CL 2017000885A1 CL 2017000885 A CL2017000885 A CL 2017000885A CL 2017000885 A CL2017000885 A CL 2017000885A CL 2017000885 A1 CL2017000885 A1 CL 2017000885A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- humanized anti
- methods
- producing
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062431P | 2014-10-10 | 2014-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000885A1 true CL2017000885A1 (es) | 2017-12-15 |
Family
ID=55130798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000885A CL2017000885A1 (es) | 2014-10-10 | 2017-04-10 | Anticuerpos anti-ox40 humanizados y usos de los mismos |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9738723B2 (enExample) |
| EP (1) | EP3204422B1 (enExample) |
| JP (2) | JP6794348B2 (enExample) |
| KR (1) | KR20170064550A (enExample) |
| CN (1) | CN107074953A (enExample) |
| AR (1) | AR102239A1 (enExample) |
| AU (1) | AU2015328090A1 (enExample) |
| BR (1) | BR112017007170A2 (enExample) |
| CA (1) | CA2963798A1 (enExample) |
| CL (1) | CL2017000885A1 (enExample) |
| CO (1) | CO2017004516A2 (enExample) |
| ES (1) | ES2914177T3 (enExample) |
| GB (1) | GB2536324A (enExample) |
| IL (1) | IL251537A0 (enExample) |
| MX (1) | MX2017004715A (enExample) |
| RU (1) | RU2709742C2 (enExample) |
| SG (1) | SG11201702826XA (enExample) |
| TW (1) | TW201619200A (enExample) |
| WO (1) | WO2016057667A1 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2687282T3 (es) | 2013-03-18 | 2018-10-24 | Biocerox Products B.V. | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos |
| BR112016013963A2 (pt) * | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
| CN106132439A (zh) | 2014-03-31 | 2016-11-16 | 豪夫迈·罗氏有限公司 | 包含抗血管发生剂和ox40结合激动剂的组合疗法 |
| RS59693B1 (sr) * | 2015-01-08 | 2020-01-31 | BioNTech SE | Agonistička sredstva za vezivanje tnf receptora |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| KR20180015650A (ko) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | 항-ox40 항체 및 이의 사용 방법 |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| WO2016196228A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
| MX2018003820A (es) | 2015-10-02 | 2018-12-10 | F Hoffmann La Roche Ag | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador. |
| JP6771551B2 (ja) | 2015-10-15 | 2020-10-21 | ディンフー バイオターゲット カンパニー リミテッド | 抗ｏｘ４０抗体及びその応用 |
| CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| IL321475A (en) | 2016-05-06 | 2025-08-01 | Medimmune Llc | Bispecific binding proteins and their uses |
| IL263834B2 (en) | 2016-06-20 | 2024-01-01 | Kymab Ltd | Anti-pd-l1 antibodies |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| EP3487533A4 (en) * | 2016-07-20 | 2020-03-25 | IGM Biosciences, Inc. | MULTIMERE OX40-BINDING MOLECULES AND USES THEREOF |
| WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| UA125041C2 (uk) | 2016-12-15 | 2021-12-29 | Еббві Байотерапьютікс Інк. | Анти-ox40 антитіла і їх застосування |
| AU2017384528A1 (en) | 2016-12-19 | 2019-07-04 | Ichnos Sciences SA | Novel TNFR agonists and uses thereof |
| WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| MX2019012464A (es) | 2017-04-20 | 2019-12-11 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. |
| WO2018193104A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-cd25 antibody-drug conjugate |
| WO2019089921A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
| AU2017440393B2 (en) * | 2017-11-24 | 2025-02-20 | Eucure (Beijing) Biopharma Co., Ltd | Anti-OX40 antibodies and uses thereof |
| CN111344019B (zh) | 2017-12-29 | 2024-03-15 | 圆祥生技股份有限公司 | 调节免疫检查点作为癌症治疗的单特异性与双特异性蛋白质 |
| CN108218990B (zh) * | 2017-12-29 | 2021-03-02 | 南京优迈生物科技有限公司 | 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用 |
| CN110092832B (zh) * | 2018-01-29 | 2020-03-31 | 康源博创生物科技(北京)有限公司 | 抗ox40抗体及其用途 |
| WO2019178852A1 (zh) * | 2018-03-23 | 2019-09-26 | 苏州丁孚靶点生物技术有限公司 | Ox40抗原多肽及其用途 |
| KR102761890B1 (ko) | 2018-03-23 | 2025-02-06 | 브리스톨-마이어스 스큅 컴퍼니 | Mica 및/또는 micb에 대한 항체 및 그의 용도 |
| CN111918873B (zh) | 2018-03-27 | 2025-06-24 | 百时美施贵宝公司 | 使用紫外线信号实时监测滴度 |
| CN110467674B (zh) * | 2018-05-11 | 2022-05-31 | 同润澳门一人有限公司 | 抗ox40的全人抗体及其制备方法和用途 |
| MX2020012567A (es) * | 2018-05-23 | 2021-01-29 | Beigene Ltd | Anticuerpos anti-ox40 y metodos de uso. |
| US20220111065A1 (en) | 2018-05-23 | 2022-04-14 | Adc Therapeutics Sa | Molecular adjuvant |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| IL280002B2 (en) | 2018-07-12 | 2025-05-01 | F Star Beta Ltd | Antibody molecules that bind CD137 and OX40 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| TWI861005B (zh) | 2018-07-12 | 2024-11-11 | 英商英沃克斯製藥有限公司 | 結合pd-l1及cd137的抗體分子 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| US20210277135A1 (en) | 2018-07-13 | 2021-09-09 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor |
| CN111040034B (zh) * | 2018-10-12 | 2022-08-30 | 广东旋玉健康生物科技有限公司 | 一种抗人cd358的单克隆抗体及其用途 |
| TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| US12269890B2 (en) | 2018-11-26 | 2025-04-08 | Nanjing GenScript Biotech Co., Ltd. | Humanized anti-human OX40 monoclonal antibody, preparation method therefor and use thereof |
| WO2020119789A1 (en) * | 2018-12-14 | 2020-06-18 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing the same, and use thereof |
| JP7346576B2 (ja) * | 2018-12-25 | 2023-09-19 | ハンクス バイオファーマシューティクス，インコーポレイテッド | 抗ｏｘ４０モノクローナル抗体とその応用 |
| US10442866B1 (en) | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| SG11202108450SA (en) | 2019-02-27 | 2021-09-29 | Ionis Pharmaceuticals Inc | Modulators of malat1 expression |
| EP3946449A4 (en) * | 2019-03-25 | 2022-11-09 | Ohio State Innovation Foundation | COMBINED IMMUNOREGULATION AND ASSOCIATED USES |
| CN114245869A (zh) | 2019-05-23 | 2022-03-25 | 百时美施贵宝公司 | 监测细胞培养基的方法 |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
| AU2020385499A1 (en) * | 2019-11-21 | 2022-06-02 | Beigene, Ltd. | Methods of cancer treatment using anti-OX40 antibodies in combination with anti-TIGIT antibodies |
| US20230011916A1 (en) * | 2019-11-21 | 2023-01-12 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| EP4061845A4 (en) * | 2019-11-21 | 2023-12-13 | BeiGene, Ltd. | METHOD FOR CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-TIM3 ANTIBODIES |
| EP4061850A4 (en) * | 2019-11-21 | 2024-03-20 | BeiGene, Ltd. | METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-PD1 OR ANTI-PDL1 ANTIBODIES |
| WO2021098749A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in combination with radiation |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| BR112022011949A2 (pt) | 2019-12-17 | 2022-11-22 | Amgen Inc | Dupla de interleucina-2/agonista do receptor tnf para uso em terapia |
| CN113429483A (zh) | 2020-03-23 | 2021-09-24 | 百奥泰生物制药股份有限公司 | 一种免疫细胞激活剂的开发及应用 |
| KR20230015327A (ko) * | 2020-04-17 | 2023-01-31 | 허치슨 메디파르마 리미티드 | 항-ox40 항체 및 이의 용도 |
| US20230183366A1 (en) * | 2020-05-13 | 2023-06-15 | Inserm (Institut National De La Santé Et De La Recherch Médicale) | Recombinant proteins with ox40 activating properties |
| CN116438199A (zh) | 2020-08-31 | 2023-07-14 | 百时美施贵宝公司 | 细胞定位特征和免疫疗法 |
| EP4225770A1 (en) | 2020-10-05 | 2023-08-16 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
| CN114457022A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用 |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
| CA3201348A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Antibody compositions and methods of use thereof |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| TW202317629A (zh) * | 2021-06-29 | 2023-05-01 | 香港商高誠生物醫藥（香港）有限公司 | 抗ｏｘ４０單株抗體及其使用方法 |
| JP2025501522A (ja) | 2021-12-17 | 2025-01-22 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗ｏｘ４０抗体及び使用方法 |
| JP2024547020A (ja) | 2021-12-17 | 2024-12-26 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗ｏｘ４０抗体、多重特異性抗体及びその使用方法 |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| JP2025509274A (ja) | 2022-03-09 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | 治療用タンパク質の一過性発現 |
| KR20240159621A (ko) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | 폴리펩티드를 단리하는 방법 |
| CN114591988B (zh) * | 2022-03-30 | 2023-01-13 | 北京贝来生物科技有限公司 | 一种激活肿瘤免疫的基因修饰干细胞制备方法 |
| IL317319A (en) | 2022-06-02 | 2025-01-01 | Bristol Myers Squibb Co | Antibody compounds and methods of using them |
| CN114966061B (zh) * | 2022-07-28 | 2022-10-21 | 中国食品药品检定研究院 | 一种抗ox40抗体的生物活性检测方法 |
| WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| AU7603800A (en) * | 1999-09-24 | 2001-04-24 | Human Genome Sciences, Inc. | 32 human secreted proteins |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| EP1725585A2 (en) | 2004-03-10 | 2006-11-29 | Lonza Ltd | Method for producing antibodies |
| CA2581208A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| HUE029789T2 (en) | 2005-05-06 | 2017-04-28 | Providence Health & Services - Oregon | Trimer OX40 Immunoglobulin Fusion Protein and Methods of Application |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| EP2441472B1 (en) * | 2006-08-21 | 2015-06-10 | F. Hoffmann-La Roche AG | Tumor therapy with an anti-VEGF antibody |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| AU2008219666A1 (en) * | 2007-02-27 | 2008-09-04 | Genentech, Inc. | Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| SI2851374T1 (sl) * | 2007-12-14 | 2017-08-31 | Bristol-Myers Squibb Company | Vezavne molekule k humanemu ox40 receptorju |
| EP2242762B1 (en) | 2008-01-18 | 2015-12-16 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| CN101952454B (zh) | 2008-02-08 | 2014-06-04 | 米迪缪尼有限公司 | 具有减弱的Fc配体亲和性的抗IFNAR1抗体 |
| NZ594315A (en) * | 2009-02-17 | 2013-05-31 | Ucb Pharma Sa | Antibody molecules having specificity for human ox40 |
| PT2663579T (pt) * | 2011-01-14 | 2017-07-28 | Univ California | Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização |
| LT2731677T (lt) * | 2011-07-11 | 2018-07-10 | Glenmark Pharmaceuticals S.A. | Antikūnai, kurie prisiriša prie ox40, ir jų panaudojimas |
| CN103946238B (zh) * | 2011-08-23 | 2016-10-12 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
| GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| CA2863818A1 (en) * | 2012-02-06 | 2013-08-15 | Brendan CURTI | Cancer treatment and monitoring methods using ox40 agonists |
| EP2819693A4 (en) * | 2012-03-02 | 2015-10-28 | Providence Health & Services Oregon | ANTICANCER BITHERAPY BASED ON OX40 / IL-2 AGONIST |
| US9243059B2 (en) * | 2013-03-12 | 2016-01-26 | Decimmune Therapeutics, Inc. | Humanized anti-N2 antibodies and methods of treating ischemia-reperfusion injury |
| ES2687282T3 (es) | 2013-03-18 | 2018-10-24 | Biocerox Products B.V. | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos |
-
2015
- 2015-10-01 TW TW104132442A patent/TW201619200A/zh unknown
- 2015-10-07 EP EP15848683.7A patent/EP3204422B1/en active Active
- 2015-10-07 WO PCT/US2015/054490 patent/WO2016057667A1/en not_active Ceased
- 2015-10-07 CA CA2963798A patent/CA2963798A1/en not_active Abandoned
- 2015-10-07 KR KR1020177012413A patent/KR20170064550A/ko not_active Withdrawn
- 2015-10-07 BR BR112017007170A patent/BR112017007170A2/pt not_active Application Discontinuation
- 2015-10-07 JP JP2017518907A patent/JP6794348B2/ja active Active
- 2015-10-07 ES ES15848683T patent/ES2914177T3/es active Active
- 2015-10-07 CN CN201580056175.7A patent/CN107074953A/zh active Pending
- 2015-10-07 AU AU2015328090A patent/AU2015328090A1/en not_active Abandoned
- 2015-10-07 RU RU2017115662A patent/RU2709742C2/ru active
- 2015-10-07 MX MX2017004715A patent/MX2017004715A/es unknown
- 2015-10-07 US US14/877,547 patent/US9738723B2/en active Active
- 2015-10-07 SG SG11201702826XA patent/SG11201702826XA/en unknown
- 2015-10-08 GB GB1517855.1A patent/GB2536324A/en not_active Withdrawn
- 2015-10-09 AR ARP150103284A patent/AR102239A1/es unknown
-
2017
- 2017-04-03 IL IL251537A patent/IL251537A0/en unknown
- 2017-04-10 CL CL2017000885A patent/CL2017000885A1/es unknown
- 2017-05-04 CO CONC2017/0004516A patent/CO2017004516A2/es unknown
- 2017-06-28 US US15/635,847 patent/US10150815B2/en active Active
-
2018
- 2018-12-10 US US16/215,263 patent/US20190169303A1/en not_active Abandoned
-
2020
- 2020-11-11 JP JP2020187650A patent/JP2021036887A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017532037A (ja) | 2017-11-02 |
| GB2536324A (en) | 2016-09-14 |
| US20180072808A1 (en) | 2018-03-15 |
| ES2914177T3 (es) | 2022-06-07 |
| AU2015328090A1 (en) | 2017-04-27 |
| JP6794348B2 (ja) | 2020-12-09 |
| US20190169303A1 (en) | 2019-06-06 |
| CN107074953A (zh) | 2017-08-18 |
| RU2709742C2 (ru) | 2019-12-19 |
| JP2021036887A (ja) | 2021-03-11 |
| TW201619200A (zh) | 2016-06-01 |
| US10150815B2 (en) | 2018-12-11 |
| CA2963798A1 (en) | 2016-04-14 |
| BR112017007170A2 (pt) | 2017-12-19 |
| CO2017004516A2 (es) | 2017-09-29 |
| WO2016057667A1 (en) | 2016-04-14 |
| MX2017004715A (es) | 2017-06-19 |
| GB201517855D0 (en) | 2015-11-25 |
| EP3204422A4 (en) | 2018-08-15 |
| RU2017115662A (ru) | 2018-11-13 |
| SG11201702826XA (en) | 2017-05-30 |
| AR102239A1 (es) | 2017-02-15 |
| EP3204422B1 (en) | 2022-03-30 |
| EP3204422A1 (en) | 2017-08-16 |
| IL251537A0 (en) | 2017-05-29 |
| KR20170064550A (ko) | 2017-06-09 |
| US9738723B2 (en) | 2017-08-22 |
| US20160137740A1 (en) | 2016-05-19 |
| RU2017115662A3 (enExample) | 2019-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000885A1 (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| DOP2021000022A (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| CL2018000458A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
| MX385585B (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
| PH12016501894B1 (en) | Anti-ox40 antibodies and methods of use | |
| MX391051B (es) | Anticuerpos anti-cd47 y usos de los mismos. | |
| ECSP17034845A (es) | Conjugados de anticuerpo- farmaco | |
| CL2017000506A1 (es) | Nuevos anticuerpos anti-mfi2 y metodos de uso | |
| MX382129B (es) | Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso. | |
| ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| CR20160270A (es) | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
| BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
| MX369623B (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
| CL2016001937A1 (es) | Compuestos de benzopirano funcionalizados y uso de los mismos | |
| BR112018012883A2 (pt) | novos anticorpos anti-upk1b e métodos de uso | |
| BR112018012884A2 (pt) | novos anticorpos anti-mmp16 e métodos de uso | |
| EA202092450A2 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей |